References

tumors

Malignant tumours

2224-50572587-6813

Rosoncoweb

10.18027/2224-5057-2012-2-90-97

tumors-120

Research Article

ОБЗОРЫ И АНАЛИТИКА

REVIEWS AND ANALYSIS

ЭКСПРЕССИОННЫЙ АНАЛИЗ МИКРОРНК ДЛЯ ДИАГНОСТИКИ И ПРОГНОЗА РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ

Поспехова

Н. И.

Поярков

С. В.

Зенит -Журавлёва

Е. Г.

Шубин

П. В.

Карпухин

А. В.

Каткова

Е. В.

Хайленко

В. А.

ФГБУ «Медико-генетический научный центр» РАМН, МоскваRussian FederationФГБУ «Российский онкологический научный центр имени Н.Н. Блохина» РАМН, МоскваRussian Federation

2012

22052015

229097

2015

Поспехова Н.И., Поярков С.В., Зенит -Журавлёва Е.Г., Шубин П.В., Карпухин А.В., Каткова Е.В., Хайленко В.А.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.malignanttumors.org/jour/article/view/120

В работе проанализированы данные научной литературы последних лет, посвящённые изучению роли микроРНК в возникновении и прогрессировании рака молочной железы, возможности использования этих молекул в качестве биомаркёров рака. Приведены результаты собственных исследований микроРНК. В работе проведен анализ уровней экспрессии 14 микроРНК, ассоциированных с развитием рака молочной железы, в 54 образцах опухолевой и нормальной ткани (27 пациентов). Показано, что паттерны экспрессии микроРНК разнообразны и пациент-специфичны. Установлен ряд закономерностей. Уровень экспрессии miR-182 повышен в 81% случаев. Экспрессия miR-31, супрессора метастазирования, подавлена в 56% случаев.

С использованием кластерного анализа выделен кластер коэкспрессии 5-ти микроРНК с преимущественно повышенной экспрессией miR-10b, miR-21, miR-155, miR-34a и miR-335. Предполагается существование ассоциации ко-экспрессирующихся в этом кластере микроРНК с патоморфологическими признаками, в том числе, преимущественным наличием метастазов. При анализе транскрипционной регуляции показано, что все микроРНК из кластера - транскрипционные мишени p53, RelA и NF-kB. Кластеризация и выделение групп микроРНК (signature) позволяют классифицировать пациентов по различным параметрам, выделять особенности, связанные с кластерами, что может расширить представление о роли микроРНК в развитии рака.

рак молочной железымикроРНКанализ экспрессии микроРНК

References1

Asaga S., Kuo C., Nguyen T. et al. Direct Serum Assay for MicroRNA-21 Concentrations in Early and Advanced Breast Cancer.// Clinical Chemistry. - 2011. - V. 57. – P. 184-91.

Augoff K., McCue B., Plow E. and Sossey-Alaoui K. miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.// Mol. Cancer – 2012. – V. 11. – P. 5-17.

Bartel D.P. MicroRNAs: target recognition and regulatory functions.// Cell. – 2009. – V. 136(2). – P. 215-33.

Chang N., Wang R., Akagi K. et al. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155.// Nature Medicine – 2011. – V. 17. – P. 1275-1283.

Eo H.S., Heo J.Y., Choi Y. et al. A pathway-based classification of breast cancer integrating data on differentially expressed genes, copy number variations and MicroRNA target genes. // Mol. Cells. – 2012.

Farazi T.A., Spitzer J.I., Morozov P., Tuschl T. miRNAs in human cancer.// J Pathol. – 2011. – V. 223(2). – P. 102-15.

Foubert E., De Craene B. and Berx G. Key signaling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression // Breast Cancer Res. – 2010. – V. 12. – P. 206-217.

Heneghan H.M., Miller N., Kelly R. et al. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. // Oncologist. – 2010. – V. 15(7) - P. 673-82.

Gabriely G., Teplyuk N.M., Krichevsky A.M. Context effect: microRNA-10b in cancer cell proliferation, spread and death. //Autophagy. - 2011 - V. 7(11). – P. 1384-6.

Guttilla I.K., White B.A. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells // J Biol Chem. – 2009. – V. 284(35). – P. 23204-16.

Janga S.C., Mittal N. Construction, structure and dynamics of post-transcriptional regulatory network directed by RNA-binding proteins.// Adv. Exp. Med. Biol. – 2011. – V. 722. – P. 103-17.

Jiang J., Sun X., Wang W. et al. Tumor microRNA-335 expression is associated with poor prognosis in human glioma//. Med. Oncol. – 2012. May 27

Jiang S., Zhang H.W., Lu M.H. et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene.// Cancer Res. – 2010. – V. 70(8). – P. 3119-27.

Kastl L., Brown I., Schofield A.C. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.// Breast Cancer Res. Treat. – 2012. – V. 131(2). – P.445-54.

Kong W., He L., CoppolaM. et al. MicroRNA-155 Regulates Cell Survival, Growth, and Chemosensitivity by Targeting FOXO3a in Breast Cancer.// J. Biol. Chem. – 2010. – V. 285(23). – P. 17869–17879.

Kong W., Yang H., He L. et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA.// Mol. Cell. Biol. – 2008. – V. 28. – P. 6773–6784.

Lu Z., Liu M., Stribinskis V. et al. microRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. // Oncogene. – 2008. – V. 27. – P. 4373–4379.

Lyng M.B., Lænkholm A.V., Søkilde R. et al. Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen monotherapy: a DBCG study.// PLoS One. – 2012. – V. 7(5). e36170

Mattie M.D., Benz C.C., Bowers J. et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies.// Mol. Cancer – 2006. – V. 5. – P. 24.

Mattiske S., Suetani R.J., Neilsen P.M., Callen DF. The Oncogenic Role of miR-155 in Breast Cancer.// Cancer Epidemiol. Biomarkers Prev. – 2012. – V. 21(8). – P. 1236-43.

Moskwa P., Buffa F.M., Pan Y. et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors.// Mol. Cell. – 2011. - V.41(2). – P. 210-20.

Niu J., Shi Y., Tan G. et al. DNA damage induces NF-κB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion.// J. Biol. Chem. – 2012. – V. 287(26). – P. 21783-95.

Ogino S., Fuchs C.S., Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine.// Expert Rev. Mol. Diagn. – 2012. – V. 12(6). – P. 621-8.

Peurala H., Greco D., Heikkinen T. et al. MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer.// PLoS One. – 2011. – V. 6(11):e26122.

Png K.J., Yoshida M., Zhang X.H. et al. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer.// Genes Dev. – 2011. – V. 25(3). – P. 226-31.

Rao X., Di Leva G., Li M. et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.// Oncogene. – 2011. – V. 30(9). – P. 1082-97.

Roth С., Rack B., Müller V. et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer // Breast Cancer Res. - 2010. – V. 12, R90.

Sato F., Tsuchiya S., Meltzer S.J., Shimizu K. MicroRNAs and epigenetics.// FEBS J. – 2011. – V. 278(10). – P. 1598-609.

Scott G.K., Goga A., Bhaumik D. Et al. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b.//J. Biol. Chem. - 2007. – V. 282(2). – P. 1479-86.

Shah M. & Calin G. MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer // Genome Medicine – 2011. – V. 3. – P. 56-59.

Si M.L., Zhu S., Wu H. et al. miR-21-mediated tumor growth. // Oncogene. – 2007. – V. 26. – P. 2799–803.

Sorlie T., Perou C.M., Tibshirani R. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications// Proc. Natl. Acad. Sci. USA. - 2001. – V. 98. – P. 10869–74.

Sorlie T., Wang Y., Xiao C. et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.// BMC. – Genomics. – 2006. – V. 7. – P. 127.

Sossey-Alaoui K., Downs-Kelly E., Das M. et al. WAVE3, an actin remodeling protein, is regulated by the metastasis suppressor microRNA, miR-31, during the invasion-metastasis cascade.// Int. J. Cancer – 2011. – V. 129(6). – P.1331-1343.

Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses.// Proc. Natl. Acad. Sci. U.S.A. – 2006. – V. 103. – P. 12481–12486.

Valastyan S., Reinhardt F., Benaich N. et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis.// Cell – 2009. – V. 137. – P. 1032-46.

Vickers M.M., Bar J., Gorn-Hondermann I. et al. Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. // Clin. Exp. Metastasis. – 2012. – V. 29(2). – P.123-32.

Voliniaa S., Galassoa M., Sanaa M. et al. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. // PNAS – 2012. – V. 109. – P. 3024–3029.

Wang H., Tan G., Dong L. et al. Circulating MiR- 125b as a marker predicting chemoresistance in breast cancer.// PLoS One. – 2012. – V. 7(4):e34210.

Yan L., Huang X., Shao Q. et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis // RNA. - 2008 – V. 14(11). - P. 2348-60.

Yan Z., Xiong Y., Xu W. et al. Identification of hsamiR-335 as a prognostic signature in gastric cancer.// PLoS One. – 2012. – V. 7(7):e40037.

Zhao J.J., Lin J., Yang H. et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. //J. Biol. Chem. – 2008. – V. 283(45). – P. 31079-86.

Zhu S., Si M.L., Wu H. et al. microRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1).// J. Biol. Chem. – 2007. – V. 282. – P. 14328–14336.

The authors declare that there are no conflicts of interest present.